Multiple Sclerosis (MS) is an unpredictable and progressive disease of the central nervous system affecting the quality of life of more than 500.000 Persons with MS, their families and their carers across Europe. To date, no cure has been found for this complex, chronic and disabling condition.



The European Multiple Sclerosis Platform (EMSP) is the Pan European association working for and with more than 30 MS national member associations / organisations to achieve its goals. Being part of a worldwide community of Persons with MS (PwMS), we are committed to dialogue with, respect for and collaboration with other stakeholders in the field of MS, particularly the Multiple Sclerosis International Federation (MSIF).


Our Vision

Throughout Europe, Persons with MS have equal access to the highest quality treatment and support they need to live their lives to the full.


Our Mission
...is to ensure the development and implementation of high quality standards of treatment and support for PwMS, their families and their carers throughout Europe, to allow them to lead their life independently and to recognise them as equal members of society.

The EMSP work priorities to achieve this mission are:

- to influence EU institutions and other decision-making bodies to improve the quality of life of PwMS
- to network with other European organizations in which the patient is central
- to provide MS member associations with information on relevant EU draft legislation and projects
- to develop and promote recommendations for improved medical treatment and rehabilitation to be implemented in the EU member states and other countries
- to encourage research of all kinds aiming at the benefit of PwMS
- to initiate and implement cross-border projects to improve the living conditions of PwMS, e.g. in the fields of therapies, employment, social security, infrastructure…
- to act as an information platform by exchanging information and best practices relevant to the work of the national MS member associations
- to enhance a general awareness on multiple sclerosis by informing and educating external audiences
- to support national MS societies both recent or long-established in Europe


Health Action International’s mission is:
a. to promote rational and economic medicines policy, therapy and use ... […]
b. to support networks, countries, groups and individuals supporting the objectives described (above). … […]…, in the broadest sense.
(HAI Foundation Document (amended 2007), Article 2.1, pg1, 1988, Amsterdam) (See Annex III)
Goal: Health Action International (HAI) is working towards a world where all people, especially the poor and disadvantaged, are able to exercise their human right to health. HAI’s goal is to achieve universal and equitable access to affordable essential medicines of assured quality and that those medicines are used rationally throughout the world.
Vision: HAI and its global partners recognise that poverty and social injustice are the greatest barriers to health and sustainable development. Partners are working for just societies where people can participate equitably in all decision making that affects their health and well being, including the allocation of resources. HAI recognises that it is only when societies enjoy sustainable levels of good health that citizens can take a full and active part in development– for development to succeed, citizens need to enjoy sustainable and predictable health and well-being.



The European Organisation for Rare Diseases, EURORDIS, is a patient-driven alliance of patient organisations and individuals active in the field of rare diseases.
EURORDIS’ mission is:
- To build a strong pan-European community of patient organisations and people living with rare diseases;
- To be their voice at the European level; and – directly or indirectly – to fight against the impact of rare diseases on their lives.

To this end, EURORDIS undertakes activities on behalf of its members, notably in favour of:
- Empowering rare disease patient groups;
- Advocating rare diseases as a public health issue;
- Raising public rare disease awareness, and also that of national and international institutions;
- Improving access to information, treatment, care, and support for people living with rare diseases;
- Encouraging good practices in relation to these;
- Promoting scientific and clinical rare disease research;
- Developing rare disease treatments and orphan drugs;
- Improving quality of life through patient support, social, welfare, and educational services.

